CAMBRIDGE, Mass., May 15 /PRNewswire-FirstCall/ -- Biopure Corporation
(Nasdaq: BPUR) announced today that A. Gerson Greenburg, M.D., Ph.D. has
joined the company as vice president of Medical Affairs. A board-certified
general surgeon and expert in oxygen therapeutics, Dr. Greenburg brings to
Biopure over 40 years of experience in clinical care, quality systems,
teaching and research. He will report to Biopure's CEO Zafiris G.
Zafirelis.
A professor emeritus of surgery at Brown University School of Medicine
in Providence, R.I., Dr. Greenburg retired from The Miriam Hospital in
April 2006 after serving as chief of clinical quality management since 2003
and as surgeon-in-chief from 1986 to 2005. In 2005, he received the
hospital's Charles C.J. Carpenter Outstanding Physician of the Year Award.
He also led the effort to organize The Miriam's submission for the
prestigious Malcolm Baldrige National Quality Award. Previously, he was
chief of general surgery and surgical intensive care at the Veterans
Administration Medical Center in San Diego, Calif., and was a professor of
surgery at the University of California, San Diego. Earlier in his career,
he served for two years as an active duty surgeon in the U.S. Air Force.
In the 1970's, Dr. Greenburg developed a method for preparing a
solution of chemically modified hemoglobin for use as a red blood cell
substitute. Since that time, his research interests have centered on the
development of oxygen therapeutics. He is past president of the
International Symposium on Blood Substitutes and a member of the
International Society of Artificial Cells & Immobilization Biotechnology's
Scientific Committee on Blood Substitutes.
Dr. Greenburg's many special appointments have included major positions
at the National Board of Medical Examiners and consulting positions at the
National Institutes of Health. He is a diplomate of the American Board of
Surgery and a member of the American College of Surgeons and several other
professional organizations. His bibliography includes over 250
publications, and he has served on the editorial board or as a reviewer for
numerous medical and scientific journals.
Dr. Greenburg served his surgical residencies in Chicago, Ill. and
completed a fellowship in trauma at Cook County Hospital. He earned his
bachelor's degree and medical degree from the University of Chicago and his
doctorate in industrial engineering/management sciences from Northwestern
University.
Biopure Corporation
Biopure Corporation develops, manufactures and markets pharmaceuticals,
called oxygen therapeutics, that are intravenously administered to deliver
oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250
(bovine)], or HBOC-201, is approved for sale in South Africa for the
treatment of surgical patients who are acutely anemic. This product has not
been approved for sale in other countries. Biopure plans to apply in
Europe, in mid 2006, for approval of an acute anemia indication in
orthopedic surgery patients. The company is developing Hemopure for a
potential indication in cardiovascular ischemia, in addition to supporting
the U.S. Naval Medical Research Center's government-funded efforts to
develop a potential out-of- hospital trauma indication. The company's
veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or
HBOC-301, the only oxygen therapeutic approved by the U.S. Food and Drug
Administration and the European Commission, is indicated for the treatment
of anemia in dogs.
Statements in this press release that are not strictly historical are
forward-looking statements, including any that might imply that the Navy's
proposed trauma trial will receive authorization to proceed or that
Hemopure will receive marketing approval in Europe or the U.S. Actual
results or their timing may differ materially from those projected in these
forward-looking statements due to risks and uncertainties. These risks
include, without limitation, uncertainties regarding the company's
financial position, unexpected costs and expenses, delays and
determinations by regulatory authorities, unanticipated problems with the
product's commercial use, whether or not product related, and with product
distributors, sales agents or other third parties, and delays in or
unpredictable outcomes of clinical trials. The company undertakes no
obligation to release publicly the results of any revisions to these
forward-looking statements to reflect events or circumstances arising after
the date hereof. A full discussion of the company's operations and
financial condition can be found in the company's filings with the U.S.
Securities and Exchange Commission, including under the heading "Risk
Factors" in the Form 10-Q filed on March 13, 2006, which can be accessed in
the EDGAR database at the SEC Web site, http://www.sec.gov.
The content of this press release does not necessarily reflect the
position or the policy of the U.S. Government or the Department of Defense,
and no official endorsement should be inferred.
Contact: Douglas Sayles Herb Lanzet (Investors)
Biopure Corporation H.L. Lanzet Inc.
(617) 234-6826 (212) 888-4570
IR@biopure.com lanzet@aol.com
SOURCE Biopure Corporation
 back to top
Related links:
http://www.biopure.com
http://www.prnewswire.com/comp/131224.html /
CONTACT:
Douglas Sayles of Biopure Corporation,
+1-617-234-6826, IR@biopure.com; or Herb Lanzet of H.L. Lanzet
Inc. for Biopure Corporation, Investors, +1-212-888-4570,
lanzet@aol.com
|
